Skip to main content

Tango Therapeutics, Inc Investor Event Transcript, Nov 10, 2026

Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics plans to begin a frontline pancreatic cancer phase three study in the first half of next year, enrolling 240 patients in each arm with response rate and progression-free survival as dual primary endpoints. AI summary

Investor Event Transcript 2026-11-10 For: 2026-12-31
Added on November 15, 2026

Conference Transcript - TNGX 2026-11-10

Michael Schmitz, Analyst — Guggenheim

I'm with Tango Therapeutics this morning. I'm Michael Schmitz, Senior Baitic Amish with Guggenheim, and with us today we have Malte Peters, CEO of Tango. Malte, welcome and thanks for joining us.

Malte Peters, M.D., CEO

Thanks, Michael, for having us. It's an honor to be here on a beautiful sunny morning in Boston, so looking forward to the chat.

Michael Schmitz, Analyst — Guggenheim

Great. So it's been a very busy year so far for Tango, especially this fall. As you look at where the company is today, how would you describe the stage Tango is in now, and what are your top priorities as you look forward?

Malte Peters, M.D., CEO

Yeah, so Tango is in full pre-submission, pre-commercial mode, and we have really done a lot of work since I joined in January as CEO to transform and evolve the company into a late-stage drug development, pre-approval, pre-commercial organization. So we have added significant expertise to our team. We have focused extremely, in a laser-sharp manner, on execution. And we are very happy with the fact that we have data that allows us actually to think about getting a drug approved. I remember when I joined the board in 2018 of Tango, the company was a discovery organization. Nobody would have thought how soon the organization would evolve into a late-stage, mature development organization, and here we are. So I think all of us at Tango are extremely happy with where we are, and we are all walking in the same direction. We have the same goals. We want to get Vopie Metastate approved, and that's what we come to work for.

Michael Schmitz, Analyst — Guggenheim

Okay. And obviously, you did have an important data presentation recently at ESMO. Maybe just to remind us, what have you learned from this combination study with Therax and RASIP and the updated ESMO data? And what gives you confidence now heading into Phase 3?

Malte Peters, M.D., CEO

Yeah, thanks. So remember, we started speaking about the data back in June. On June 8th was the first day when we disclosed the combination data. At that time, we had a denominator of 12 patients. At that time, we had a 92% response rate. And three months later, or four months later, in October, we presented an update of that data set with a denominator of 22 patients in pancreatic cancer. So out of 22 patients, we have now a response rate of 82%. We have four out of five patients with non-small cell lung cancer responding. Funding, so that makes an 81% response rate, combining PDAC and non-small cell lung cancer patients. That's a very, very reassuring data set, and the data set is corroborated or reinforced or supported by the fact that the responses are very durable. So we have a PFS rate at nine months of 88%. If you look at the second-line patients only, not a single patient has progressed, so the curve is actually at the 100% mark, and we still have a very attractive and very favorable safety profile. We have no grade 3 rash, we have no grade 3 stomatitis and mucositis, and that's why we feel very strongly about the data set, and that's why at ESMO we disclosed our plan to start a frontline study. A phase three study in front-line pancreatic cancer in the first half of next year.

Michael Schmitz, Analyst — Guggenheim

There were... I think the combination worked broadly across KRAS, MTAP double mutation patients, but I don't think there were KRAS G12D patients in the cohort specifically. How confident are you that the combination works there as well?

Malte Peters, M.D., CEO

Yeah, that's true, because remember, the study is a two-armed study. We have the Dioxin-Rasip combination arm, and we have the Zoldan-Rasip combination arm, and so far, all of the G2FD patients flowed into the Zoldan arm, but we have now put a handful of G2FD patients on the Dioxin-Rasip arm as well. It's a bit early to say what the efficacy is. We have no reason to really believe or assume that the responses will be any less than in the other mutations. That position is also supported by the fact that we have a very high efficacy rate in the G12R patients. So G12R patients are very difficult to treat. Dioxin-Rasip monotherapy yields a 7% response rate in our patients, and we have observed 50% response rate in these patients. So we are very confident that we see a high degree of synergy in the G2FD patients as well.

Michael Schmitz, Analyst — Guggenheim

Yeah. And true synergy is not very common, I think, in oncology drug development. We've seen it in the MACB rough space where you see synergy. But I guess, is there a mechanistic explanation that could explain why this combination is so synergistic?

Malte Peters, M.D., CEO

We think, so there's no real one mechanism where we say, okay, that's the secret to explain the synergy. We know that the pathways are interacting and that the degree of synergy is tightly related to where the drugs actually operate in these pathways. Our preclinical experiments suggested a high degree of synergy, and we are super happy that we could confirm the synergy in the clinic, which, as you know, sometimes is not the case, right? You have extremely, you can have extremely encouraging data in the laboratory, which then failed to translate in the clinic. In our case, we actually confirmed the synergy in the clinical experiments, in the clinical setting of the study.

Michael Schmitz, Analyst — Guggenheim

And can you remind us what you've seen in combination with Zoldan-Rasib, the 12D inhibitor? In general, the mutant selective inhibitors have been generating higher response rates on their own than the pan-Rasib inhibitors. And I'm just curious what your thoughts are on that other part of your combination study.

Malte Peters, M.D., CEO

Yeah, so we have, if you look at the waterfall plot of the Zoldan-Rasib combination, it's still extremely attractive. The response rates are very effective, but the response rates are lower than in the Diracson-Rasip curve. We think we understand why. We think we need to hit the Ras-Y type component of the whole pathway. And we think we do this very effectively with Diracson-Rasip and not as strongly with Zoldan-Rasip. So we think we understand why there's a difference in response rate between Diracson-Rasip combination with VOPI and Zoldan-Rasib with VOPI.

Michael Schmitz, Analyst — Guggenheim

Okay. And then tolerability, as you mentioned, looked very good for the Daraxin-Rasib-VOPI metastate combination. Do you think there's real potential differentiation compared to the known monotherapy efficacy of each drug?

Malte Peters, M.D., CEO

Yeah, we think so. And if you look at the safety tolerability profile of Daraxin-Rasib alone, It's now very well understood and very well published. We see significantly less skin toxicity and mucositis and stomatitis. We think we understand why. Our hypothesis is that dioxin racin leads to a downregulation of phosphorac in the skin. Vopimidastat or PMT5 inhibition does the opposite. It upregulates phosphor or ERK in the skin, so we counterbalance or counteract mechanistically the way how patients develop skin toxicity. So that's the reason why we think we have such an attractive safety and tolerability profile. And that's extremely attractive for patients because a grade 3 rash, grade 3 stomatitis, mucositis is not nice. It's not a good toxicity to have. So if we can make it more acceptable for patients, I think we have something extremely attractive for people. Yeah.

Michael Schmitz, Analyst — Guggenheim

And then could you walk us through the frontline phase 3 trial design in pancreatic cancer? You obviously did Maybe you could have interactions with the FDA. Maybe remind us what their feedback was that then resulted in this particular study design.

Malte Peters, M.D., CEO

Yeah, and maybe I go a tiny bit into the past and say that Tango has developed a very, very good report with FDA. It started actually when we had our first monotherapy discussions with FDA. So FDA knows the safety profile of Volpi metastat very well, and they're very comfortable with the data set. That's, I think, a reason why FDA was very supportive when we presented our trial design. So the study we suggested to FDA was a one-to-one randomized clinical trial of 240 patients in each arm. We are proposing, and FDA was fully in line with this, response rate and progression-free survival as dual primary endpoints. And we basically had no major area of discussions with the agency. So they were very comfortable with our dose proposal. So they were very comfortable with the statistical analysis plan. So it was one of the nicest meetings I can recall with the agency.

Michael Schmitz, Analyst — Guggenheim

And what is the gating factor at this point to starting the study?

Malte Peters, M.D., CEO

Operations, operations, operations. The reason why we focus so much on discussing the frontline study with FDA is that we know all the details that now have to be worked on to get the study started. So we needed to have an agreement on the protocol design in order to approach the sites, in order to work with the CROs, in order to get the study off the ground. And luckily, we are at that point, and the study startup activities are in full swing, and that's a great place to be. Okay.

Michael Schmitz, Analyst — Guggenheim

And I'm not sure if you can answer this question, but obviously you don't yet have PFS from your Phase 2 study. What are the underlying PFS powering assumptions for the Phase 3 in frontline?

Malte Peters, M.D., CEO

Yeah, so that's a topic we typically try to avoid to discuss in public, essentially because FDA doesn't really like companies to go into the details of statistical analysis plan discussions. They prefer that companies are a little bit uptight about this or confidential about it. So, I will follow that advice and will not disclose any details of the SAP here. Okay.

Michael Schmitz, Analyst — Guggenheim

And can you comment on how the response rate analysis is being done, and could that lead to an early filing or an accelerated approval application?

Malte Peters, M.D., CEO

So, I think what I would say is that the choice of the endpoints are response rate and PFS. As dual primary endpoints, gives us flexibility to monitor the trial and to have a discussion with FDA about what the ideal moment could be to have a submission as early as possible. So I think that's really attractive. Of course, we will do the PFS and over-survival analysis. We think it will strengthen our data package, but the design itself gives us great flexibility to discuss with the agency about, you know, their willingness to consider an earlier time point of submission.

Michael Schmitz, Analyst — Guggenheim

Okay. And something we get asked sometimes is, so given the drug-drug interaction, the Rats and Rasp is dosed at one-third of its single-agent dose at 100 mix per day. I guess in practice, how would you handle necessary dose reductions in that case, given this is already the lowest tablet strength that's available?

Malte Peters, M.D., CEO

Yeah, it's actually very convenient because we have very good data showing that if you decrease the volpilometastat dose, you contemporaneously decrease the darks and rassib exposure as well. That's the nature of the drug-drug interaction. So this works in our favor here. So we intend, in case we need it, to lower the Vopi-Metastat dose, and by lowering the Vopi-Metastat dose, we automatically will reduce the exposure to darks and raseps. So that's a fairly easy way to react in case patients develop toxicities that make that necessary. Okay.

Michael Schmitz, Analyst — Guggenheim

And in phase three, you're obviously comparing doublet compared to chemotherapy. Is there anything else necessary to show contribution of components for the combination?

Malte Peters, M.D., CEO

So that's a part that we have not yet discussed with FDA. So that's potentially a topic that we will address when we talk to FDA about a possible accelerated approval in our second-line study. We did not have enough time in our first meeting with FDA to touch on all the components of the second-line submission or second-line strategy. We will do this very soon, and then we know how FDA is thinking about the contribution of components. But today, we don't have a real yay or nay on a potential way forward here or on potential solution. So, we are a little bit vague on the contribution of components side.

Michael Schmitz, Analyst — Guggenheim

So, yeah, my next question then was, where are you with your second-line PDAC plan? So, it sounds like the study and potentially accelerated approval there is still a priority for you.

Malte Peters, M.D., CEO

It's still a priority. We ranked the order of priority by frontline first and then second line second because of the operational complexity of starting a big phase three study in frontline, but we are highly committed to move as quickly as we can in second line. Again, we expect to have a moment with the FDA before the end of the year potentially to discuss our second line strategy. The FDA is very interested in that component, in that discussion, so they have indicated that they are highly interested in discussing with us. We have a study that's open for enrollment as we speak, as you know, so we will discuss various options with the agency of how we could potentially discuss an accelerated approval in second line.

Michael Schmitz, Analyst — Guggenheim

Okay. And so there's been some investor focus on the fact that you actually do not have We have a supply agreement with Revolution Medicines in place today for the Phase III study with Theraxin-Rasip. Maybe talk about your ability to execute on a study without that, and is that still something that you're hoping to do?

Malte Peters, M.D., CEO

Yeah, so that's one of the most frequently asked questions we get. We have an existing supply agreement with RevMed for the ongoing study. We do not have one for the frontline study that is scheduled to start next year. We always said, I personally spoke to this many times, that our preference would be to continue the collaboration with RevMed. We like it. We like their drug. So we are currently figuring out the two companies of how we can continue the collaboration negotiations are ongoing as we speak. That's clearly one option. But we also understand here at Tango that in case something gets in the way of finding an agreement for a continuation of a supply agreement, we will not lose any time and we will continue to start and execute without any delay. That's why we had confidence enough at ESMO to say that we are going to start the frontline study in the first half of next year. Here, for us at Tango, the key component is speed. So, we think the data is so significant and so... It's very important for the field and for the patient that we have to do everything in our power to get the study started as quickly as we can. We would love to do it with RevNet, clearly our preference, but if something gets in the way, we will do it without.

Michael Schmitz, Analyst — Guggenheim

Okay, and how does your collaboration with Araska fit into the picture and the development path?

Malte Peters, M.D., CEO

So, we like the Araska collaboration a lot. We think they have a very attractive molecule. I think one of the... A very smart decision at Tango was to enter an agreement with Erasca at the beginning of this year. We just released information, I think it was last week that we started the frontline, excuse me, the first in man study of Erasca 0015 and Vopi-Medistat. So we are moving very quickly. The interest at Erasca is very high. The interest at Tango is very high to move the collaboration forward. And I think we need a tiny bit more to figure out a comprehensive development plan. But as soon as we have agreement between the two companies, we will declare ourselves and we will show a bit more details. Okay.

Michael Schmitz, Analyst — Guggenheim

Then, obviously, the data that is presented has not gone unnoticed by other companies, and so there are a number of other PRMT5 inhibitor pan-ras combinations, you know, in the works, contemplate already ongoing. And so, do you see, how do you see the PMT5-inhibitor landscape evolving as these other combinations are being developed as well? Do you see differentiation of Wopi Metastat, for example, from other PMT5-inhibitors, or are these all going to be similar?

Malte Peters, M.D., CEO

So, we are a very confident organization now, and we can say we strongly believe that we have the best PMT5-inhibitor. And we are convinced that we will be able to bring the best PMT5 inhibitor to the market first. So the reason I'm saying that is that we think the combinability of PMT5 inhibition with other molecules is going to be probably the key differentiator between the different PMT5 inhibitors that you currently have available or that are currently in drug development. Our molecule has an extremely good safety and tolerability profile. It has a very high potency, and the combination data that we have disclosed with Dioxin-Rasib and Zoldan-Rasib are supporting that notion. So we don't think that there's going to be a lot of differentiation between the different PMT5 inhibitors on the efficacy side, but we think the differentiation will probably emerge in the safety, intolerability, and combinability side. And we think on that front, we are ahead of everybody else. Okay.

Michael Schmitz, Analyst — Guggenheim

And so beyond pancreatic cancer, how do lung cancer and GBM fit into your program?

Malte Peters, M.D., CEO

Yeah, so lung cancer is a very attractive indication. At Tango, we are in a lucky position that we have two very good PMT5 inhibitors. We have Vopimetastat, which in our eyes is the ideal molecule for pancreatic cancer. It does not cross the blood-brain barrier. It has a very good safety tolerability profile, the right drug-like properties for patients with pancreatic cancer. We have TNG456, which crosses the blood-brain barrier, and that's a feature that you need if you develop a PMT5 inhibitor in non-small cell lung cancer because 30 to 50 percent of patients with non-small cell lung cancer have brain meds. So the brain meds are horrible for patients, and there are a very big headache for doctors treating these patients. So when we speak to lung cancer docs, they say, oh, give us a PMT5 inhibitor that potentially can address the brain metastases, and we're very happy that we have that with TNG-456. So, Beginning of 27, in January, we are going to share some ideas of how we develop TNG-456 in non-small cell lung cancer. And it may come to a point where we say we have a dichotomy. Volpimata set for pancreatic cancer, 456 for non-small cell lung cancer.

Michael Schmitz, Analyst — Guggenheim

And just help us understand what you've guided to this first lung cancer update to be, sort of how many patients, any comments you can provide there.

Malte Peters, M.D., CEO

We haven't really spoken about it, but the number will be high enough for us to make a decision of which drug we want to take where. So that's the reason why we waited a tiny bit longer until we were confident to stick our head out. We think January is the right time, and we will have a good data set that will be informative for the market.

Michael Schmitz, Analyst — Guggenheim

Okay. And what is the bar for TNG-456 to advance in glioblastoma, which is another MTAP-driven condition?

Malte Peters, M.D., CEO

Yeah, glioblastoma is a difficult indication. It's very clear. Our study is in relapsed refractory patients. Glioblastoma docs are convinced that the truth lies in the adjuvant setting. So we will see if the data will be attractive enough to go forward into GBM, and we will share some thoughts on our GBM development strategy also in January.

Michael Schmitz, Analyst — Guggenheim

So maybe then just to wrap up, which of the two or three key milestones of the next 12 months or so matter most for Tango, in your opinion?

Malte Peters, M.D., CEO

So it's clearly the initiation of the frontline study in pancreatic cancer. It's clearly our understanding of a comprehensive regulatory strategy in frontline and second-line pancreatic cancer. It's clearly our understanding of where we will go forward in non-small cell lung cancer. I think these are the three biggest components of our... Catalyst.

Michael Schmitz, Analyst — Guggenheim

Okay, great. Well, thank you, Malte. We'll wrap up here, but appreciate it. Thank you, Michael.

Malte Peters, M.D., CEO

Pleasure being here, and thanks again.

Michael Schmitz, Analyst — Guggenheim

Great. Thank you.